[
    [
        {
            "time": "2019-04-30",
            "original_text": "【西南医药】医药行业2018年年报及2019年一季报总结：行业分化明显，疫苗、CRO和药店等表现抢眼",
            "features": {
                "keywords": [
                    "医药行业",
                    "年报",
                    "一季报",
                    "行业分化",
                    "疫苗",
                    "CRO",
                    "药店"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "疫苗",
                    "CRO",
                    "药店"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【西南医药】医药行业2018年年报及2019年一季报总结：行业分化明显，疫苗、CRO和药店等表现抢眼",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-05-10",
            "original_text": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
            "features": {
                "keywords": [
                    "板块分化",
                    "投资策略",
                    "兴证医药",
                    "投资月报"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "板块分化后的投资策略 ——兴证医药2019年5月投资月报",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-05-15",
            "original_text": "【招商医药】医药生物行业18年年报及19年一季报回顾--医药整体业绩探底，内部分化明显",
            "features": {
                "keywords": [
                    "医药生物",
                    "年报",
                    "一季报",
                    "业绩探底",
                    "内部分化"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【招商医药】医药生物行业18年年报及19年一季报回顾--医药整体业绩探底，内部分化明显",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-05-20",
            "original_text": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
            "features": {
                "keywords": [
                    "医药",
                    "年报",
                    "季报",
                    "野蛮扩张",
                    "结构优化",
                    "医药流通"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医药流通"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国盛医药张金洋团队】年报季报验证医药从野蛮扩张到结构优化，继续推荐医药流通",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        }
    ]
]